Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, reported positive twelve-month clinical data relating to the safety and efficacy of its TTX-381 program at the 19th International Congress on Neuronal Ceroid Lipofuscinosis (NCL) in Queensland, Australia.

Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, reported positive twelve-month clinical data relating to the safety and efficacy of its TTX-381 program at the 19th International Congress on Neuronal Ceroid Lipofuscinosis (NCL) in Queensland, Australia.

Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, today announced that TTX-381 has been awarded the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) innovative medicine designation. TTX-381 is a novel one-time investigational gene therapy product being developed for the treatment of the ocular manifestations of CLN2 disease, a form of Batten disease.

Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, today announced that TTX-381 has been awarded the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) innovative medicine designation. TTX-381 is a novel one-time investigational gene therapy product being developed for the treatment of the ocular manifestations of CLN2 disease, a form of Batten disease.

Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, today announced that TTX-381 has been awarded the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) innovative medicine designation. TTX-381 is a novel one-time investigational gene therapy product being developed for the treatment of the ocular manifestations of CLN2 disease, a form of Batten disease.

Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TTX-381. TTX-381 is a novel one-time gene therapy product being developed for the treatment of the ocular manifestations of CLN2 disease, a form of Batten disease.

Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, today announced that TTX-381, the company’s investigational therapy to treat the ocular manifestations of CLN2 disease, has been selected by the U.S. Food and Drug Administration (FDA) to participate in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program.

Tern Therapeutics, LLC (“Tern”), a biotechnology company developing transformative one-time gene therapies for rare diseases, today announced that TTX-381, the company’s investigational therapy to treat the ocular manifestations of CLN2 disease, has been selected by the U.S. Food and Drug Administration (FDA) to participate in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program.